Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.
Saved in:
| Title: | Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. |
|---|---|
| Authors: | Tang ASP; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Hsu JTY; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Chong SKS; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Quek J; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Shek G; Wallace Wurth, University of New South Wales, Sydney, NSW, Australia., Sulaimi F; Wallace Wurth, University of New South Wales, Sydney, NSW, Australia., Chan KE; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Anand VV; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore., Chong B; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Mehta A; Virginia Commonwealth University Health Pauley Heart Center, Division of Cardiology (A.M.), Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, USA., Toh SA; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Medicine, National University Hospital, Singapore, Singapore.; NOVI Health, Singapore, Singapore.; Regional Health System Office, National University Health System, Singapore, Singapore., Muthiah M; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore., Dimitriadis GK; Department of Endocrinology ASO/EASO COM, King's College Hospital NHS Foundation Trust, London, UK.; Obesity, Type 2 Diabetes and Immunometabolism Research Group, Department of Diabetes, Faculty of Cardiovascular Medicine & Sciences, School of Life Course Sciences, King's College London, London, UK., le Roux CW; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.; Diabetes Research Centre , Ulster University , UK, UK., Chan MY; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore., Mamas MA; Keele Cardiac Research Group, Keele University, Stoke-on-Trent, UK., Chin YH; Ministry of Health Holdings, Ministry of Health, Singapore, Singapore., Chew NWS; NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Nicholas_WS_Chew@nuhs.edu.sg.; Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore. Nicholas_WS_Chew@nuhs.edu.sg. |
| Source: | Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Jul 12; Vol. 24 (1), pp. 285. Date of Electronic Publication: 2025 Jul 12. |
| Publication Type: | Journal Article; Meta-Analysis; Systematic Review |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1475-2840 |
|---|---|
| DOI: | 10.1186/s12933-025-02840-3 |
